PL3661520T3 - Terapia adiuwantowa do stosowania w leczeniu raka prostaty - Google Patents

Terapia adiuwantowa do stosowania w leczeniu raka prostaty

Info

Publication number
PL3661520T3
PL3661520T3 PL18705663T PL18705663T PL3661520T3 PL 3661520 T3 PL3661520 T3 PL 3661520T3 PL 18705663 T PL18705663 T PL 18705663T PL 18705663 T PL18705663 T PL 18705663T PL 3661520 T3 PL3661520 T3 PL 3661520T3
Authority
PL
Poland
Prior art keywords
prostate cancer
cancer treatment
adjuvant therapy
adjuvant
therapy
Prior art date
Application number
PL18705663T
Other languages
English (en)
Inventor
F.M.J. Debruyne
Original Assignee
Fund Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Sa filed Critical Fund Sa
Publication of PL3661520T3 publication Critical patent/PL3661520T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL18705663T 2017-08-01 2018-02-23 Terapia adiuwantowa do stosowania w leczeniu raka prostaty PL3661520T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17184320 2017-08-01
PCT/EP2018/054470 WO2019025031A1 (en) 2017-08-01 2018-02-23 ADJUVANT TREATMENT FOR USE IN THE TREATMENT OF PROSTATE CANCER
EP18705663.5A EP3661520B1 (en) 2017-08-01 2018-02-23 Adjuvant therapy for use in prostate cancer treatment

Publications (1)

Publication Number Publication Date
PL3661520T3 true PL3661520T3 (pl) 2022-03-28

Family

ID=59520769

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18705663T PL3661520T3 (pl) 2017-08-01 2018-02-23 Terapia adiuwantowa do stosowania w leczeniu raka prostaty

Country Status (12)

Country Link
US (2) US11771705B2 (pl)
EP (1) EP3661520B1 (pl)
JP (3) JP2020530031A (pl)
CN (1) CN111295192A (pl)
BR (1) BR112020002094A2 (pl)
CA (1) CA3071660A1 (pl)
ES (1) ES2906380T3 (pl)
MY (1) MY197942A (pl)
PL (1) PL3661520T3 (pl)
RU (1) RU2758386C2 (pl)
SG (1) SG11202000881VA (pl)
WO (1) WO2019025031A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3661520T3 (pl) * 2017-08-01 2022-03-28 Fund Sa Terapia adiuwantowa do stosowania w leczeniu raka prostaty
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
DE60318092T2 (de) * 2002-10-23 2008-11-27 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
ES2346053T3 (es) * 2002-11-08 2010-10-08 Pantarhei Bioscience B.V. Sintesis de esterol a traves de esteroides derivados de estrona.
EP1617859A1 (en) * 2003-04-30 2006-01-25 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
WO2005063276A1 (en) * 2003-12-23 2005-07-14 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
WO2009137080A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
JP2012077020A (ja) * 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
PL3661520T3 (pl) * 2017-08-01 2022-03-28 Fund Sa Terapia adiuwantowa do stosowania w leczeniu raka prostaty

Also Published As

Publication number Publication date
CN111295192A (zh) 2020-06-16
JP2025081385A (ja) 2025-05-27
WO2019025031A1 (en) 2019-02-07
EP3661520A1 (en) 2020-06-10
JP2020530031A (ja) 2020-10-15
RU2758386C2 (ru) 2021-10-28
CA3071660A1 (en) 2019-02-07
JP2023085303A (ja) 2023-06-20
RU2020108631A (ru) 2021-09-02
RU2020108631A3 (pl) 2021-09-02
US20230405019A1 (en) 2023-12-21
BR112020002094A2 (pt) 2020-07-28
US11771705B2 (en) 2023-10-03
SG11202000881VA (en) 2020-02-27
MY197942A (en) 2023-07-25
EP3661520B1 (en) 2021-12-01
US20200246354A1 (en) 2020-08-06
ES2906380T3 (es) 2022-04-18

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
IL271946A (en) Combination for cancer treatment
SG11202104356VA (en) Bt1718 for use in treating cancer
IL267795A (en) Combined treatment for cancer
IL255060A0 (en) Combined treatment for cancer
IL256224B (en) Combined therapy for cancer treatment
LT3423087T (lt) Kompleksinė priešvėžinė terapija
IL258521A (en) Combination of treatments for cancer treatment
IL275517A (en) Combined methods and treatment of cancer
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL280830A (en) Bracelets for use in cancer treatment methods
IL266993A (en) Combined therapy for cancer treatment
SG11202000881VA (en) Adjuvant therapy for use in prostate cancer treatment
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer
PT3258931T (pt) Utilização do cabazitaxel no tratamento do cancro da próstata
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201704909D0 (en) Cancer therapy
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
IL253642A0 (en) Combined treatment for cancer
GB201711855D0 (en) Cancer therapy
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy